In Reply We thank Fan and colleagues for their interest in our recent phase 1/2 trial evaluating the use of chemoradiotherapy with a simultaneous integrated boost of radiation in unresectable locally advanced esophageal cancer.1 First, we are delighted to present more details regarding the cohort of 97 patients used for comparison in our investigation. This patient cohort is the same group we used as the historical control in our previous interim analysis,2 in which we described the selection criteria. Briefly, all 97 of the historical cohort patients with unresectable esophageal cancer were treated at the University of Texas MD Anderson Cancer Center with chemoradiation (50.4 Gy in 28 fractions) using intensity-modulated radiotherapy and a simultaneous integrated boost. The patients were reviewed from an accessible partial data set of 239 total patients previously created from a separate analysis.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chen D, Menon H, Welsh J. Using Real-World Historical Controls to Evaluate Radiation Dose Escalation in Esophageal Cancer—Reply. JAMA Oncol. Published online February 06, 2020. doi:10.1001/jamaoncol.2019.6412
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: